Диссертация (1154718), страница 19
Текст из файла (страница 19)
[et al.]. Trends in the incidence ofdeep vein thrombosis and pulmonary embolism: a 25-year population-based study.// Archives of internal medicine. 1998. № 6 (158). C. 585–93.155. Smeeth L., Cook C., Thomas S. [et al.]. Risk of deep vein thrombosis andpulmonary embolism after acute infection in a community setting // The Lancet.2006. № 9516 (367). C. 1075–1079.156.
Spector E.B., Grody W.W., Matteson C.J. [et al.]. Technical standards andguidelines: venous thromboembolism (Factor V Leiden and prothrombin 20210G>A testing): a disease-specific supplement to the standards and guidelines forclinical genetics laboratories. // Genetics in medicine : official journal of the123American College of Medical Genetics. № 6 (7). C. 444–53.157. Spencer F.A., Emery C., Joffe S.W. [et al.].
Incidence rates, clinical profile,and outcomes of patients with venous thromboembolism. The Worcester VTEstudy // Journal of Thrombosis and Thrombolysis. 2009. № 4 (28). C. 401–409.158. Spencer F.A., Emery C., Lessard D. [et al.]. The worcester venousthromboembolism study // Journal of General Internal Medicine. 2006. № 7 (21).C. 722–727.159. Spencer F.A., Gore J.M., Lessard D. [et al.]. Patient Outcomes After DeepVein Thrombosis and Pulmonary Embolism<subtitle>The Worcester VenousThromboembolism Study</subtitle> // Archives of Internal Medicine.
2008.№ 4 (168). C. 425.160. Springer J., Villa-Forte A. Thrombosis in vasculitis. // Current opinion inrheumatology. 2013. № 1 (25). C. 19–25.161. Stassen P.M., Derks R.P.H., Kallenberg C.G.M. [et al.]. Venousthromboembolism in ANCA-associated vasculitis--incidence and risk factors //Rheumatology. 2007. № 4 (47).
C. 530–534.162. Stuijver D.J.F., Majoor C.J., Zaane B. van [et al.]. Use of oral glucocorticoidsand the risk of pulmonary embolism: a population-based case-control study. //Chest. 2013. № 5 (143). C. 1337–42.163. Stuijver D.J.F., Majoor C.J., Zaane B. van [et al.]. Use of OralGlucocorticoids and the Risk of Pulmonary Embolism // Chest. 2013. № 5 (143).C. 1337–1342.164. Sweetland S., Green J., Liu B. [et al.]. Duration and magnitude of thepostoperative risk of venous thromboembolism in middle aged women:prospective cohort study.
// BMJ (Clinical research ed.). 2009. (339). C. b4583.165. Sykes T.C., Fegan C., Mosquera D. Thrombophilia, polymorphisms, andvascular disease. // Molecular pathology : MP. 2000. № 6 (53). C. 300–6.166. Szamosi S., Csiki Z., Szomják E. [et al.]. Plasma homocysteine levels, theprevalence of methylenetetrahydrofolate reductase gene C677T polymorphism andmacrovascular disorders in systemic sclerosis: risk factors for accelerated124macrovascular damage? // Clinical reviews in allergy & immunology. 2009.
№ 2–3(36). C. 145–9.167. Tagalakis V., Patenaude V., Kahn S.R. [et al.]. Incidence of and Mortalityfrom Venous Thromboembolism in a Real-world Population: The Q-VTE StudyCohort // The American Journal of Medicine. 2013. № 9 (126). C. 832.e13832.e21.168. Thögersen A.M., Jansson J.H., Boman K. [et al.]. High plasminogen activatorinhibitor and tissue plasminogen activator levels in plasma precede a first acutemyocardial infarction in both men and women: evidence for the fibrinolytic systemas an independent primary risk factor. // Circulation.
1998. № 21 (98). C. 2241–7.169. Tichelaar Y.I.G.V., Kluin-Nelemans H.J.C., Meijer K. Infections andinflammatory diseases as risk factors for venous thrombosis. A systematic review.// Thrombosis and haemostasis. 2012. № 5 (107). C. 827–37.170. Topaloglu R., Akierli C., Bakkaloglu A. [et al.]. Survey of factor V leiden andprothrombin gene mutations in systemic lupus erythematosus. // Clinicalrheumatology. 2001. № 4 (20). C. 259–61.171.
Tsai A.W., Cushman M., Rosamond W.D. [et al.]. Coagulation factors,inflammationmarkers,andvenousthromboembolism:thelongitudinalinvestigation of thromboembolism etiology (LITE) // The American Journal ofMedicine. 2002. № 8 (113). C. 636–642.172. Tybjaerg-Hansen A., Agerholm-Larsen B., Humphries S.E.
[et al.]. Acommon mutation (G-455--> A) in the beta-fibrinogen promoter is anindependent predictor of plasma fibrinogen, but not of ischemic heart disease. Astudy of 9,127 individuals based on the Copenhagen City Heart Study. // Journal ofClinical Investigation. 1997. № 12 (99).
C. 3034–3039.173. Tzoran I., Brenner B., Papadakis M. [et al.]. VTE Registry: What Can BeLearned from RIETE? // Rambam Maimonides medical journal. 2014. № 4 (5). C.e0037.174. Vayá A., Santaolaria M., Micó L. [et al.]. Thrombotic events in systemiclupus erythematosus. Its association with acquired and inherited thrombophilic125defects. // Clinical hemorheology and microcirculation. 2008. № 2 (40). C. 79–87.175. Verso M., Agnelli G., Ageno W.
[et al.]. Long-term death and recurrence inpatients with acute venous thromboembolism: The MASTER registry //Thrombosis Research. 2012. № 3 (130). C. 369–373.176. Wartiovaara U., Perola M., Mikkola H. [et al.]. Association of FXIIIVal34Leu with decreased risk of myocardial infarction in Finnish males. //Atherosclerosis. 1999. № 2 (142). C. 295–300.177. Weidner S., Hafezi-rachti S., Rupprecht H.D. Thromboembolic events as acomplication of antineutrophil cytoplasmic antibody–associated vasculitis //Arthritis & Rheumatism.
2006. № 1 (55). C. 146–149.178. White R.H., Chan W.-S., Zhou H. [et al.]. Recurrent venousthromboembolismafterpregnancy-associatedversusunprovokedthromboembolism. // Thrombosis and haemostasis. 2008. № 2 (100). C. 246–52.179. Wilcken D. EL MTHFR 677C→T mutation, folate intake, neural-tube defect,and risk of cardiovascular disease // The Lancet. 1997. № 9078 (350). C.
603–604.180. Wilhelmsen L., Svärdsudd K., Korsan-Bengtsen K. [et al.]. Fibrinogen as aRisk Factor for Stroke and Myocardial Infarction // New England Journal ofMedicine. 1984. № 8 (311). C. 501–505.181.Wille-JørgensenP.,JorgensenL.N.,CrawfordM.Asymptomaticpostoperative deep vein thrombosis and the development of postthromboticsyndrome. A systematic review and meta-analysis. // Thrombosis and haemostasis.2005.
№ 2 (93). C. 236–41.182. Wirchov R.L.K. Thrombose und embolie 1998.183. Wolff S.M., Fauci A.S., Horn R.G. [et al.]. Wegener’s granulomatosis. //Annals of internal medicine. 1974. № 4 (81). C. 513–25.184. Wu A.R., Garry J., Labropoulos N. Incidence of pulmonary embolism inpatients with isolated calf deep vein thrombosis // Journal of Vascular Surgery:Venous and Lymphatic Disorders.
2017. № 2 (5). C. 274–279.185. Xiao H., Schreiber A., Heeringa P. [et al.]. Alternative complement pathwayin the pathogenesis of disease mediated by anti-neutrophil cytoplasmic126autoantibodies. // The American journal of pathology. 2007. № 1 (170). C. 52–64.186. Xu J., Lupu F., Esmon C.T. Inflammation, innate immunity and bloodcoagulation. // Hamostaseologie. 2010. № 1 (30). C. 5–6, 8–9.187. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE,Evans A, Luc G, Cambou JP et al. The 4G/5G genetic polymorphism in thepromoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated withdifferences in plasma PAI-1 activity but not with risk of myocardial infarction inthe ECTIM study. Etude CasTemoins de I’nfarctus du M // Thromb Haemost.1995.
№ 3 (74). C. 837–841.188. Zito F., Castelnuovo A. Di, Amore C. [et al.]. Bcl I polymorphism in thefibrinogen beta-chain gene is associated with the risk of familial myocardialinfarction by increasing plasma fibrinogen levels. A case-control study in a sampleof GISSI-2 patients. // Arteriosclerosis, thrombosis, and vascular biology.
1997. №12 (17). C. 3489–94.189. Zivelin A., Griffin J.H., Xu X. [et al.]. A single genetic origin for a commonCaucasian risk factor for venous thrombosis. // Blood. 1997. № 2 (89). C. 397–402.190. Zöller B., Dahlbäck B. Linkage between inherited resistance to activatedprotein C and factor V gene mutation in venous thrombosis. // Lancet (London,England). 1994. № 8912 (343). C. 1536–8.191.
Zubrow M.T., Urie J., Jurkovitz C. [et al.]. Asymptomatic deep veinthrombosis in patients undergoing screening duplex ultrasonography. // Journal ofhospital medicine. 2014. № 1 (9). C. 19–22..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
